Categories: Business

US Intel establishes two new divisions, focusing on software and HPC

US semiconductor giant Intel announced on the 22nd that it will establish two new divisions. It will be a software-focused division and a high-performance computing (HPC) and graphics semiconductor division.

In addition, Sandra Rivera and Raja Koduri, who are currently in executive positions, have announced that they will take up new positions. Nick McCune and Greg Lavender have also announced their joining the company.

Lavender will be an executive in the new software and advanced technology division. Until recently, he was Senior Vice President and Chief Technology Officer (CTO) of VMware.

Koduri will be head of the computing systems and graphics division. Compete with NVIDIA, which manufactures semiconductors for graphics.

Rivera, McCune, Lavender and Raja Koduri will report to Pat Gelsinger’s CEO.

Jimmy Fraley

Recent Posts

GRUPO ELEKTRA ANNOUNCES REVENUE OF Ps.40,045 MILLION AND EBITDA OF Ps.4,119 MILLION IN THE THIRD QUARTER OF 2022

Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA* Latibex: XEKT), Latin America's leading specialty retailer and financial services…

2 years ago

mCloud Announces Proposed Unsecured Loan from Strategic Investors

mCloud Technologies Corp. (Nasdaq: MCLD) (TSX-V: MCLD), ("mCloud" or the "Company") a leading provider of AI-powered asset…

2 years ago

TransPerfect Acquires Sterling Technology

TransPerfect, the world's largest provider of language and technology solutions for global business, announced that…

2 years ago

Comerica Incorporated Names Kelly Gage, Director of Investor Relations; Darlene Persons to Retire on April 1

Comerica Incorporated (NYSE: CMA) announced that Kelly Gage, National Director of Sales and Strategy for the Commercial Bank…

2 years ago

Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic

Genomadix announced it has entered into a know-how license agreement and stock purchase agreement with…

2 years ago

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the…

2 years ago

This website uses cookies.